Stretch and anesthetic dependency of atrial natriuretic peptide release demonstrated by an ultrastructural assay.
Using an ultrastructural assay developed to quantify the secretion of atrial natriuretic peptide-containing granules, release of the hormone, in response to different degrees of atrial distension, is directly demonstrated at the cellular level. The ultrastructural assay developed uses an in situ tannic acid perfusion technique to arrest the exocytosis of atrial granules in the anesthetized rat. Secretory granules, which retain the capacity to undergo exocytosis throughout a 30-minute tannic acid perfusion, accumulate at the cell surface in a state of fusion with the plasma membrane, with the core contents retained. Quantification of arrested granules thus provides a measure of the rate of granule release and allows the responses to different stimuli to be assessed. By altering the height of the perfusate, perfusion pressure and hence the degree of distension of the right atrium can be increased, and this causes a proportional rise in the release of secretory granules from individual myocytes. An anesthetic regime incorporating fentanyl citrate was found to increase significantly the rate of granule release, and this was further augmented by atrial distension. Quantification of the numbers of cytoplasmic granules under the same conditions did not reveal a reduction in granules. This is thought to be because only a small pool of granules is recruited for exocytosis, and granule production may continue during the perfusion period. Our assay of atrial secretory granule release allows the effect of a variety of stimulatory and inhibitory agents to be assessed directly at the cellular level and provides an independent comparison with previous biochemical data from whole animal and isolated organ studies.
Newman
T M
TM
Department of Cardiac Medicine, National Heart and Lung Institute, London, United Kingdom.
Severs
N J
NJ
D000777:Anesthetics / Q000494:pharmacology*; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000378:metabolism*; D001463:Barbiturates / Q000494:pharmacology; D002090:Butyrophenones / Q000494:pharmacology; D003594:Cytoplasmic Granules / Q000378:metabolism / Q000648:ultrastructure; D004338:Drug Combinations; D005089:Exocytosis / Q000187:drug effects; D005283:Fentanyl / Q000494:pharmacology; D006321:Heart / Q000187:drug effects; D006325:Heart Atria; D008874:Midazolam / Q000494:pharmacology; D009206:Myocardium / Q000166:cytology / Q000378:metabolism* / Q000648:ultrastructure; D010812:Physical Stimulation; D051381:Rats; D017207:Rats, Sprague-Dawley
D000777:Anesthetics; D001463:Barbiturates; D002090:Butyrophenones; D004338:Drug Combinations; C001432:Hypnorm; D009320:Atrial Natriuretic Factor; D008874:Midazolam; D005283:Fentanyl; C032232:barbituric acid